tetano
Editor, Senior Moderator
J Glob Health
. 2024 Jul 19:14:04126.
doi: 10.7189/jogh.14.04126. Cost-effectiveness of seasonal influenza vaccination in WHO-defined high-risk populations in Bangladesh
Md Zakiul Hassan[SUP] 1 2 [/SUP], Md Abdullah Al Jubayer Biswas[SUP] 1 [/SUP], Tahmina Shirin[SUP] 3 [/SUP], Mahmudur Rahman[SUP] 4 [/SUP], Fahmida Chowdhury[SUP] 1 [/SUP], Eduardo Azziz-Baumgartner[SUP] 5 [/SUP], William W Davis[SUP] 5 [/SUP], Mofakhar Hussain[SUP] 6 [/SUP]
Affiliations
Background: Bangladesh carries a substantial health and economic burden of seasonal influenza, particularly among the World Health Organization (WHO)-defined high-risk populations. We implemented a modelling study to determine the cost-effectiveness of influenza vaccination in each of five high-risk groups (pregnant women, children under five years of age, adults with underlying health conditions, older adults (≥60 years), and healthcare personnel) to inform policy decisions on risk group prioritisation for influenza vaccination in Bangladesh.
Methods: We implemented a Markov decision-analytic model to estimate the impact of influenza vaccination for each target risk group. We obtained model inputs from hospital-based influenza surveillance data, unpublished surveys, and published literature (preferentially from studies in Bangladesh, followed by regional and global ones). We used quality-adjusted life years (QALY) as the health outcome of interest. We also estimated incremental cost-effectiveness ratios (ICERs) for each risk group by comparing the costs and QALY of vaccinating compared to not vaccinating each group, where the ICER represents the additional cost needed to achieve one year of additional QALY from a given intervention. We considered a willingness-to-pay threshold (ICER) of less than one gross domestic product (GDP) per capita as highly cost-effective and of one to three times GDP per capita as cost-effective (per WHO standard). For Bangladesh, this threshold ranges between USD 2462 and USD 7386.
Results: The estimated ICERs were USD -99, USD -87, USD -4, USD 792, and USD 229 per QALY gained for healthcare personnel, older adults (≥60), children aged less than five years, adults with comorbid conditions, and pregnant women, respectively. For all risk groups, ICERs were below the WHO willingness-to-pay threshold for Bangladesh. Vaccinating pregnant women and adults with comorbid conditions was highly cost-effective per additional life year gained, while vaccinating healthcare personnel, older adults (≥60), and children under five years were cost-saving per additional life year gained.
Conclusions: Influenza vaccination to all target risk groups in Bangladesh would be either cost-saving or cost-effective, per WHO guidelines of GDP-based thresholds.
. 2024 Jul 19:14:04126.
doi: 10.7189/jogh.14.04126. Cost-effectiveness of seasonal influenza vaccination in WHO-defined high-risk populations in Bangladesh
Md Zakiul Hassan[SUP] 1 2 [/SUP], Md Abdullah Al Jubayer Biswas[SUP] 1 [/SUP], Tahmina Shirin[SUP] 3 [/SUP], Mahmudur Rahman[SUP] 4 [/SUP], Fahmida Chowdhury[SUP] 1 [/SUP], Eduardo Azziz-Baumgartner[SUP] 5 [/SUP], William W Davis[SUP] 5 [/SUP], Mofakhar Hussain[SUP] 6 [/SUP]
Affiliations
- PMID: 39024624
- PMCID: PMC11257706
- DOI: 10.7189/jogh.14.04126
Background: Bangladesh carries a substantial health and economic burden of seasonal influenza, particularly among the World Health Organization (WHO)-defined high-risk populations. We implemented a modelling study to determine the cost-effectiveness of influenza vaccination in each of five high-risk groups (pregnant women, children under five years of age, adults with underlying health conditions, older adults (≥60 years), and healthcare personnel) to inform policy decisions on risk group prioritisation for influenza vaccination in Bangladesh.
Methods: We implemented a Markov decision-analytic model to estimate the impact of influenza vaccination for each target risk group. We obtained model inputs from hospital-based influenza surveillance data, unpublished surveys, and published literature (preferentially from studies in Bangladesh, followed by regional and global ones). We used quality-adjusted life years (QALY) as the health outcome of interest. We also estimated incremental cost-effectiveness ratios (ICERs) for each risk group by comparing the costs and QALY of vaccinating compared to not vaccinating each group, where the ICER represents the additional cost needed to achieve one year of additional QALY from a given intervention. We considered a willingness-to-pay threshold (ICER) of less than one gross domestic product (GDP) per capita as highly cost-effective and of one to three times GDP per capita as cost-effective (per WHO standard). For Bangladesh, this threshold ranges between USD 2462 and USD 7386.
Results: The estimated ICERs were USD -99, USD -87, USD -4, USD 792, and USD 229 per QALY gained for healthcare personnel, older adults (≥60), children aged less than five years, adults with comorbid conditions, and pregnant women, respectively. For all risk groups, ICERs were below the WHO willingness-to-pay threshold for Bangladesh. Vaccinating pregnant women and adults with comorbid conditions was highly cost-effective per additional life year gained, while vaccinating healthcare personnel, older adults (≥60), and children under five years were cost-saving per additional life year gained.
Conclusions: Influenza vaccination to all target risk groups in Bangladesh would be either cost-saving or cost-effective, per WHO guidelines of GDP-based thresholds.